Order Entry
United States
ContactUsLinkComponent
functional IGFBP-3 LIA, Eagle Biosciences, Inc.
functional IGFBP-3 LIA, Eagle Biosciences, Inc.
Catalog # 102994-274
Supplier:  Eagle Biosciences
CAS Number:  
functional IGFBP-3 LIA, Eagle Biosciences, Inc.
Catalog # 102994-274
Supplier:  Eagle Biosciences
Supplier Number:  E04A
CAS Number:  

Some Products May Appear Restricted

To ensure a smooth and speedy checkout, please log in to your account. Some items may show as restricted simply because you're not logged in.

If you do not have an account, you can register using our registration webform (https://www.avantorsciences.com/us/en/login/register)

 

If you're still seeing restrictions after logging in, certain products—like chemicals or medical devices—require additional account verification steps to be able to place an order. Some items may additionally require a specific license or customer documentation;  additional documentation will be requested for these items prior to shipment. 

Specifications

  • Description:
    functional IGFBP-3 LIA
  • Size:
    1 kit
  • Cat. No.:
    102994-274
  • Supplier no.:
    E04A

Specifications

About this item

The Eagle Biosciences IGFBP-3 LIA utilizes specific and high affinity antibodies for IGFBP-3.

  • Sensitivity: 0.4 ng/mL
  • Dynamic Range: 0.4 - 30 ng/mL
  • Incubation Time: 3.5 hours

All currently existing IGFBP-3 immunoassays use the binding of specific anti-IGFBP-3 antibodies for signal generation and thus IGFBP-3 quantification. The failure of differentiation between complete IGFBP-3 molecules and their respective fragments (derived physiologically due to the different proteases activities) is unavoidable in this system. Because one molecule IGFBP-3 can be cleaved in several fragments often false high quantitative values are measured. Based on this methodology it is not possible to differentiate between high IGFBP-3 levels in fact, or, a high degree of fragmentation. The incidental attempts to use monoclonal antibodies with a binding region represented only by the intact IGFBP-3 molecule are indirect, imprecise and insufficient. The activities of all effective proteases, which have different sites of action and therefore generate different kind of fragments, are disregarded.